跳至主要内容
临床试验/NCT03154580
NCT03154580已完成1 期

Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users: A Pilot Test of Glutamatergic Modulation

Wayne State University1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2017年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
21
试验地点
1
主要终点
Subjective Effects Scale Visual Analog Scale (VAS) (Self-report measure)

研究概览

简要总结

The purpose of the proposed study is to examine the relationship between marijuana reminders, or "cues", craving for marijuana, and marijuana use. The principal investigator is also assessing whether N-acetylcysteine, can reduce marijuana craving or use.

详细描述

This study involves three screening sessions that could last about 3 hours each.

Part of this study will be conducted on an inpatient unit where the participant will live for 4 straight nights.

During the inpatient stay participants will participant in experimental sessions where they will be asked to smoke cigarettes containing either marijuana or placebo (a blank). Participants will be asked to take capsules that could contain N-acetylcysteine or placebo (blank).

Participants will be asked to complete questionnaires and have vital signs (blood pressure, heart rate) monitored.

Participants will be asked to participate in overnight sleep recordings, a polysomnogram (PSG).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Participants will be healthy individuals 21-55 year olds who use marijuana.
  • Marijuana use will be verified by self-report and THC-positive urine samples. -Participants must meet DSM 5 criteria for Cannabis Use Disorder and be willing to participate in research but not seeking treatment.

排除标准

  • Candidates with the following conditions will be excluded:
  • Serious psychiatric illness (e.g. psychotic or bipolar disorder
  • Recent (past 5 years) suicide attempts
  • Major depression that is not substance-induced)
  • Substance Use Disorders (SUD) other than Cannabis or Nicotine Use Disorders and Mild Alcohol Use Disorder
  • Neurological diseases (e.g. stroke, seizures)
  • Cardiovascular problems (e.g. myocardial infarction, angina, systolic BP >160 or <95 mmHg, diastolic BP >95 mmHg, clinically abnormal ECG)
  • Pulmonary diseases (e.g. asthma, TB)
  • Systemic diseases (e.g. hepatitis, autoimmune, Cushing syndrome)
  • Cognitive impairment (<80 IQ)
  • Past-month exposure to medications that increase study risk (e.g. toxicity to major organs, asthma inhalers)
  • Women who are pregnant (urine HCG), lactating (self-report), or if heterosexually active and not using (self-report) medically approved birth control measures (oral/depot contraceptives, IUD, condom/foam, sterilization, tubal ligation)
  • Seeking treatment for a Substance Use Disorder.
  • Individuals unable to give voluntary informed consent will be excluded. Applicants interested in treatment will be excluded from the study and referred to a treatment program.

研究组 & 干预措施

N-acetylcysteine 0mg X Cue Exposure (neutral)

Placebo Comparator

干预措施: N-acetyl cysteine (Drug)

N-acetylcysteine 0mg X Cue Exposure (marijuana)

Placebo Comparator

干预措施: N-acetyl cysteine (Drug)

N-acetylcysteine 2400mg X Cue Exposure (neutral)

Active Comparator

干预措施: N-acetyl cysteine (Drug)

N-acetylcysteine 2400mg X Cue Exposure (marijuana)

Active Comparator

干预措施: N-acetyl cysteine (Drug)

结局指标

主要结局

Subjective Effects Scale Visual Analog Scale (VAS) (Self-report measure)

时间窗: Change is being assessed. Subjective Effects Scale administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.

Marijuana Withdrawal Checklist

时间窗: Change is being assessed. Questionnaire is administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.

Systolic blood pressure (physiological effects)

时间窗: Change is being assessed. Systolic blood pressure measured at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.

Diastolic blood pressure (physiological effects)

时间窗: Change is being assessed. Diastolic blood pressure measured at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.

Core-body temperature (physiological effects)

时间窗: Change is being assessed. Core-body temperature measured at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.

Marijuana Craving Questionnaire (Self-report measure)

时间窗: Change is being assessed. Marijuana Craving Quest.administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.

Marijuana Rating Form (Self-report measure)

时间窗: Change is being assessed. Marijuana Rating Form administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.

Questionnaire of Smoking Urges (Self-report measure)

时间窗: Change is being assessed. Questionnaire is administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.

NAC Side Effect Checklist

时间窗: Change is being assessed. Questionnaire is administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.

Marijuana Craving Visual Analog Scale (VAS) (Self-report measure)

时间窗: Change is being assessed. Marijuana Craving VAS administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1250, 1310, 1320, 1330, 1345, 1400, 1430, 1500, 1530, and 1600.

Heart rate (physiological effects)

时间窗: Change is being assessed. Heart rate measured at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Leslie Lundahl

Principal Investigator

Wayne State University

研究点 (1)

Loading locations...

相似试验

Marijuana Cue-Reactivity & Seeking Behavior in... | 临床试验